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A microwave accelerated simple and eﬃcient method for the construction of the 1,5-tetrazole 
scaﬀold was developed. It comprises a multicomponent reaction of an amine, a carboxylic acid 
derivative, and an azide source. On the basis of the availabililty of the archetypical starting materials, 
this method provided very versatile synthetic access to 1,5-disubstituted tetrazoles. The usefulness 
of this method was demonstrated in the synthesis of biologically important fused tetrazole scaﬀolds 
and the marketed drug cilostazol.
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The tetrazole motif is an important synthetic scaﬀold that is widely use in medicine, biochemistry, 
pharmacology, and materials; for example, this structure is found in explosives, photography and 
photoimaging chemicals, rocket propellants, polymers, gas generators, and agrochemicals.[1] The 
ﬁrst tetrazole synthesis was reported in 1885.[2] Since then, a plethora of examples has been reported, 
the vast majority of which rely on the use of nitriles, heterocumulenes, amides, thioamides, imidoyl 
chlorides, ketones, amines, and alkenes as the starting materials.[3] The increasing importance of 
1,5-disubstituted tetrazoles in diﬀerent applications, including as bio-active agents;[1c] drugs such as 
cilostazol pentylenetetrazole, and latamoxef; and cis-amide bond isosteres in peptides, has propelled 
the need for eﬃcient synthetic methods. Direct access to diverse 1,5-disubstituted tetrazoles is 
mainly possible from amides and thioamides.[4] Other methods include the use of ketones and 






.[5] Recently, various methods 
were developed for the synthesis of 1,5-disubstituted tetrazoles from amides.[3a] These methods 
mainly use chlorinating agents to form imidoyl chlorides, followed by the addition of an azide source 
to give the disubstituted tetrazoles. However, the limited availability of diverse amides as starting 
material compels an additional step for amide synthesis from carbonyl compounds such as acids 
and acetyl chlorides. Moreover, direct amide bond formation from unactivated acids is challenging 
and thus, multistep sequential syntheses are often the result.[6] Direct amide formation requires 
basic conditions, whereas tetrazole formation is favored in acidic conditions through the formation 
of the imidoyl chloride, which make a one-pot synthesis of tetrazoles diﬃcult. Also the one-pot 
reaction for the synthesis of tetrazoles from amides is challenging, as hydrogen chloride formed in 
the chlorination step can have deleterious eﬀects on acid-sensitive functionalities.[7] 
 Reported methods for tetrazole formation from amides face major drawbacks, including the use 
of an excess amount of toxic, volatile, and highly explosive HN
3
, long reaction time,[8] racemization 
of the product,[9] and the use of Mitsunobu reaction conditions, which require expensive reagents, 
long reaction times, and tedious workup procedures and with low yields.[10] The use excess of base 
to trap HCl generated in the reaction,[7] in addition to an excess amount NaN
3
 increases the chances 





 combination was reported for the one-step synthesis of tetrazoles from amides, 
but the major drawbacks of this method are the requirement of anhydrous and inert conditions, long 
reaction time (50 h), and limited reported diversity.[13] Thus, the development of a straightforward, 
easy, safe, eﬃcient, fast, diverse, and general method for the formation of tetrazoles form unactivated 
carbonyl compounds is warranted. We foresaw that the accelerating eﬀect of microwaves could 
potentially lead to a multicomponent reaction (MCR) of tetrazoles among suitable carbonyl 
compounds, amines and azide with a chlorinating agent. We hypothesized that, in situ amide 
formation from amines and carbonyl compounds followed by imidoyl chloride formation and ﬁnally 
a tetrazole formation by azide addition would be possible in a one-pot three-component reaction 
(3CR). Careful choice of a suitable chlorinating reagent could trigger activation for both amide and 
imidoyl chloride formation as the key step of the reaction.
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To test this hypothesis, optimization of the reaction was performed with hydrocinnamoyl chloride, 
benzylamine, and TMS-azide as starting materials with diﬀerent chlorinating reagents, solvents, 
temperatures, microwave conditions, reaction times. Initially screening was performed at room 







 at room temperature or heating, and with the use of diﬀerent solvents, 
including CH
3
CN, DMF, THF, 2,6-lutidine, but we did not get the expected product. The reactions 
mostly ended up in amide formation, and even reﬂuxing for 3 days in the presence of excess amount 
HCl, the product was not formed. We shifted to POCl
3
, which is safer alternative to phosgene and 
easier to handle than PCl
5
. Encouragingly, we found a trace product formation with POCl
3
 at room 
temperature after a long reaction time (3 days) (Table 1). An increase in the temperature led to a 
slight enhancement in the reaction conversion, but the reaction still gave the amide as the major 
product. The use of a base to reduce the requisite amount of HCl in the reaction did not have 
any eﬀect on the reaction. The synthesis of tetrazoles by using nitriles and NaN
3
 at 220 °C under 
microwave conditions is known,[14] and this encouraged us to try microwave conditions at higher 
temperature. A reaction at 150 °C gave the product but required 25 minutes to obtain complete 
conversion. Increasing the temperature to 180 °C accelerated the reaction to 3 minutes with 100 
% conversion. We used 1.5 equivalents of TMS-azide which avoids the danger of forming hydrazide 
from excess azide.
Table 1. Optimization of MCR with diﬀerent reaction conditions.a
Entry Catalyst/Additive Solvent Temp °C Time Yield(%)c
1 HCl CH
3










CN 80 1 day 10
4 SOCl
2

























CN 150b 20 min 70
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CN 180b 5 min 72
aThe reaction was carried out with 1mmol 1, 1 mmol 2, 1.5 mmol TMSN
3
 and 1 mmol POCl
3
. bmicrowave heating cYield of isolated 
product, nr = no reaction. 
With these optimized conditions at hand, we next examined the generality of this novel 3CR by 
treating diﬀerent carbonyl compounds like acid chlorides, carboxylic acids, and esters with diﬀerent 
amines (Table 2). The majority of the acid chlorides gave complete conversion into the corresponding 
tetrazoles under these optimized conditions in good to high yields (Table 2, entries 1–17). Aromatic 
and aliphatic acid chloride compounds proved to be equally eﬀective in this reaction. The functional 
group tolerance of the acid chloride (e.g., methoxy, nitro and chloro; (Table 2, entries 4–7 and 12–
14) in this protocol provides multiple opportunities for various further chemical manipulations. 
The conversions of aromatic and aliphatic carboxylic acids were as eﬀective as those of the acid 
chlorides, but these substrates delivered the products in slightly lower yields. 
 Application of this method to esters was also successful; however, a longer reaction time was 
required (25–30 min) for total conversion, and moderate to good yields were provided with aliphatic 
and aryl esters. Esters with nitrile and chloro substituents also displayed decent reactivity in this 
reaction (Table 2, entries 29–31). Aliphatic and aromatic amine compounds were compatible 
substrates for this process. Good conversions were also observed in case of sterically hindered 
groups, including 2-chloroaniline, 2-benzyl-aniline, and 2-methylaniline, which provided the product 
in good to excellent yields of 91, 80, and 72%, respectively (Table 2, entries 6, 15, and 17). Amine 
derivatives containing both electron-withdrawing and donating functionalities such as methoxy, 
chloro, and nitrile were equally compatible and aﬀorded the expected adducts. Easily cleavable 
groups such as cyanoethyl and benzyl were also compatible with this method, and they readily 
give access of 1H-5-tetrazoles (Table 2, entries 2, 11, and 26). Bistetrazoles are also accessible via 
our method (Table 2, entries 37–40), and these compounds are highly important in high-energy 
nitrogen-rich compounds and in polymerization.[15]
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Table 2. Synthesis of tetrazoles from carbonyl compounds, amines and TMS-azide.a



























































































































































































































































































































































-o-Cl 25 60 (3af)
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aThe reaction was performed with 1 (1mmol), 2 (1 mmol), TMSN
3 
(1.5 mmol), and POCl
3 
(1 mmol). bcy = cyclohexyl, iPr = isopropyl, 




 (3 equivalents) were used.
The use of PCl
5
 in the synthesis of amino acid tetrazoles often results in racemization of the 
products, as ketamine formation leads to racemization and careful control over the amount of base 
is required.[16] To check the stereochemical retention of our method, we used N-benzyloxycarbonyl 
(Cbz)-L-alanine (4) and benzyl amine (5) for the synthesis of the amino acid tetrazole 6 (Scheme 1). 
To our delight, the reaction proceeds under full stereoretention, as shown by chiral HPLC on a chiral 
stationary phase (see experimental part). Our method, therefore, provides enantiopure product 
likely by avoiding the use of a base. This opens the opportunity to introduce chiral tetrazoloamino 
acids into peptides.
Scheme 1. Synthesis of amino acid tetrazole.
Next, we tried to access more elaborated fused tetrazole scaﬀolds. We envisaged a second strategy 
by exploiting a MCR for the synthesis of fused tetrazoles. Multicomponent reactions have lately 
emerged as a powerful tool in synthesis of biologically important diverse scaﬀolds. Even though 
fused tetrazole possess a wide spectrum of biological activities only very limited access to these 
fused tetrazole is currently possible by simple one-pot MCR.[1,17] For example, fused tetrazoles are 
accessible via isocyanide-based synthesis of tetrazoles followed by cyclization.[18] Using our highly 
ﬂexible and robust methodology, we foresaw a quick and easy access to therapeutically interesting 
complex molecular structures.
 According to our synthetic plan, the use of functionalized carboxylic acid with amines 
bearing additional functional groups would allow an anticipated domino-cyclization process in 
one step. The reaction of formamide, which works as an ammonia and formaldehyde surrogate, 
and 2-aminobenzoic acid under optimized conditions led to the formation of the tetrazolo[1,5-c]
quinazoline scaﬀold in moderate yield (Table 3, entry 1).
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Biologically important tetrazolo[1,5-a]quinoxaline derivatives[19] were synthesized by using 2-oxoacids 
or their sodium salt with o-phenylenediamine, and they generally worked well with complete 
reaction conversion with good yields (Table 3, entries 2–4). 4-Methyl-4,5-dihydrotetrazolo[1,5-a]
quinoxaline was formed by the reaction of 2-chloropropanoyl chloride and o-phenylenediamine 
(Table 3, entry 5). Tetrazolo[5,1-a]phthalazine (Table 3, entry 6), for example, was reported as an 
anticonvulsant.[20] Using our method, the reaction between hydrazine, 2-formylbenzoic acid, and 
TMS-azide permitted the construction of tetrazolo[5,1-a]phthalazine in one step in 48% yield. Next, 
we attempted the synthesis of 4H-benzo[b]tetrazolo[1,5-d][1,4]oxazine, which is an antidepressant/ 
anxiolytic agent.[21] Treating 2-aminophenol with 2-chloro acetyl chloride in the presence of TMS-
azide allows the preparation of a tetrazole ring fused to a benzooxazine (Table 3, entry 7). 
 Pentylenetetrazole (PTZ) is a GABA
A 
receptor antagonist and prototypical anxiogenic drug 
that is used experimentally as a probe to study seizure phenomena.[22] It is typically synthesized 
by multi-step method starting with caprolactame to form the imino ether followed by addition of 
hydrazine to form hydrazine derivatives, which are further treated with nitrous acid to ﬁnally aﬀords 
the targets.[23] We hypothesized that PTZ could rapidly be accessed through a three-center, two-
component reaction between commercially available and inexpensive 6-aminohexanoic acid and 
TMS-azide. We isolated this compound in a good 76% yield by using our one-pot method after 
reaction time of 8 min (Table 3, entry 10).
Table 3. Synthesis of 1,5-fused tetrazole from carboxylic acid derivatives, amine and TMSN
3
.a
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COOH 5 67 (9i) N
N
NN
aThe reaction was performed with 7 (1 mmol), 8 (1 mmol), and TMSN
3
 (1.5 mmol). bYield of isolated product. c ormamide used as 
solvent. dExcess amount of hydrazine hydrate was used.
Finally, we validated our novel one-pot synthetic pathway towards preparation of the marketed 
drug Cilostazol, which targets phosphodiesterase and inhibits platelet aggregation. It is employed 
as a direct arterial vasodilator. Notably, this drug is usually synthesized by multistep procedures, 




.[24] Our rapid two-step Cilostazol synthesis involves 
the 3CR of 5-chloropentanoic acid chloride 10, cyclohexyl amine 11, and TMS-azide to form the 
tetrazole intermediate 12, which was followed by coupling with commercially available 6-hydroxy-
3,4-dihydro-2(1H)-quinolinone 13 (Scheme 2). 





 at 180 °C in a microwave to form tetrazole 12, but we observed the formation 
of several side products, likely involving nucleophilic substitution reactions. Then, we sequentially 





 and heated reaction at 120 °C for 10 minutes. Tetrazole 12 could be 
isolated in good yields. Coupling of 12 with 13 under microwave heating at 150 °C for 7 minutes 
aﬀorded Cilostazol 14 in 89% yield (Scheme 2). 
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Scheme 2. Two-step synthesis of Cilostazol by our MCR methodology.
Conclusion
In conclusion, we developed a novel, eﬃcient, safe, and general microwave-assisted ﬁrst-in-class 
MCR-based methodology to gain access to diverse and fused tetrazoles in a single step. Multiple 
inter- and intramolecular examples pinpoint the versatility of the reaction. Use of TMSN
3
 in an 
almost equimolar ratio makes the process safer than reported protocols. Moreover, the synthetic 
utility of this developed methodology was illustrated in the synthesis of biologically active 1,5-fused 
tetrazoles, an amino acid tetrazole and the marketed drug Cilostazol.
Experimental Procedures and Spectral Data
CAUTION: Great caution should be exercised during addition of compounds as gas evolves. Proper 
protective measures like proper shielding and an additional safety screen in the fume hood, safety 
glasses, lab coat, gloves, should be used. The reactions described here were run on only 1–5 mmol 
scale. Use clean and scratch free microwave vial as during the reaction pressure create (up to 14 bar). 
Residual pressure should be relieved before opening the vessel by carefully puncturing the septum 
with a needle. Many tetrazole derivatives are known to be explosive. Functional groups known to be 
cleavable in acidic conditions like t-butyl or t-octyl (1,1,3,3-tetramethylbutyl) as amine source were 
avoided; as these groups may cleave under the reaction conditions and may form the free tetrazole 
which are explosive. Also derivatives containing a high number of nitrogens weren’t pursued, as 
increasing the nitrogen atoms may lead to an increase in the risk for an explosion.
510585-L-sub01-bw-Ajay
Processed on: 30-5-2017 PDF page: 121




General procedure for the synthesis of tetrazole: 
A 20 ml microwave vial equipped with a magnetic stirring bar was charged with carbonyl compound 
(1.0 mmol) in CH
3
CN (5 ml) and amine (1.0 mmol) was added slowly followed by phosphoryl chloride 
(1.0 mmol) and trimethylsilyl azide (1.5 equiv) at room temperature. The vial was sealed with a cap 
containing a septum and subjected to microwave heating at 180 °C [attention: during irradiation, 
pressure develops] till completion of the reaction (monitored by TLC). Then the reaction mixture was 
poured into 50 mL of saturated NaHCO
3




. The solvent was 
removed under reduced pressure and the residue was puriﬁed by silica gel ﬂash chromatography 
using EtOAc–hexane or DCM:MeOH as eluent. [Caution: Addition of reagents and work-up must be 
done in a fumehood.]
Spectral Data
5-benzyl-1-phenethyl-1H-tetrazole (3a)
Black viscous liquid, Yield: 180 mg (68%); 1H NMR (500 MHz, CDCl
3
) δ 7.36 – 7.22 
(m, 6H), 7.04 (d, J = 7.0, 2H), 6.96 – 6.87 (m, 2H), 4.30 (t, J = 7.1, 2H), 3.80 (s, 2H), 2.99 (t, 
J = 7.1, 2H); 13C NMR (126 MHz, CDCl
3
) δ 153.9, 136.4, 133.9, 129.1, 129.0, 128.9, 128.8, 
128.7, 128.5, 127.7, 127.4, 48.8, 36.1, 28.9; MS (ESI) m/z calculated [M+H]+: 265.14; 
found [M+H]+: 265.18.
1-benzyl-5-phenethyl-1H-tetrazole (3b)
Brown solid, Yield: 190 mg (72%); 1H NMR (500 MHz, CDCl
3
) δ 7.37 – 7.31 (m, 3H), 7.30 
– 7.22 (m, 3H), 7.12 – 7.01 (m, 4H), 5.20 (s, 2H), 3.01 (s, 4H); 13C NMR (126 MHz, CDCl
3
) 
δ 154.5, 139.4, 133.3, 129.3, 129.2, 128.91, 128.8, 128.4, 127.5, 127.4, 126.9, 50.5, 33.4, 
25.6; MS (ESI) m/z calculated [M+H]+: 263.14; found [M+H]+: 263.16.
5-phenethyl-1-propyl-1H-tetrazole (3c)
Brown liquid, Yield: 168 mg (78%);1H NMR (500 MHz, CDCl
3
) δ 7.30 – 7.23 (m, 3H), 
7.13 (d, J = 7.2, 2H), 3.93 (t, J = 7.3, 2H), 3.18 (dd, J = 11.3, 4.4, 2H), 3.11 (dd, J = 11.6, 
4.5, 2H), 1.78 – 1.71 (m, 2H), 0.86 (t, J = 7.4, 3H); 13C NMR (126 MHz, CDCl
3
) δ 154.1, 
139.5, 128.8, 128.81, 128.6, 128.4, 126.9, 126.4, 48.3, 33.7, 25.6, 22.9, 10.9; MS (ESI) 
m/z calculated [M+H]+: 217.14; found [M+H]+: 217.27.
5-(4-chlorobenzyl)-1-(4-methoxyphenethyl)-1H-tetrazole (3d) 
Yellow liquid, Yield: 251 mg (76%); 1H NMR (500 MHz, CDCl
3
) δ 7.26 (d, J = 8.6, 
2H), 6.95 (d, J = 8.3, 2H), 6.85 – 6.73 (m, 4H), 4.29 (t, J = 6.8, 2H), 3.78 (s, 3H), 3.72 
(s, 2H), 3.02 (t, J = 6.8, 2H); 13C NMR (126 MHz, CDCl
3
) δ 158.9, 153.5, 133.6, 132.2, 
129.8, 129.7, 129.2, 128.8, 128.2, 114.4, 55.3, 49.1, 35.2, 28.3; MS (ESI) m/z calculated 
[M+H]+: 329.11; found [M+H]+: 329.15.
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Brown liquid, Yield: 218 mg (73%); 1H NMR (500 MHz, CDCl
3
) δ 7.36 – 7.14 (m, 5H), 7.00 
– 6.87 (m, 4H), 4.33 (t, J = 6.9, 2H), 3.69 (s, 2H), 3.07 (t, J = 6.9, 2H); 13C NMR (126 MHz, 
CDCl
3
) δ 153.6, 136.4, 133.6, 132.2, 129.8, 129.2, 129.1, 129.1, 128.9, 128.7, 127.5, 48.9, 
36.1, 28.3; MS (ESI) m/z calculated [M+H]+: 299.10; found [M+H]+: 299.15.
5-(4-chlorobenzyl)-1-(2-chlorophenyl)-1H-tetrazole (3f) 
Brown solid, Yield: 279 mg (91 %); 1H NMR (500 MHz, CDCl
3
) δ 7.33 (m, 3H), 
7.24 – 7.19 (m, 3H), 6.98 – 6.91 (m, 2H), 3.58 (s, 2H); 13C NMR (126 MHz, CDCl
3
) 
δ 153.5, 133.7, 133.1, 130.9, 130.3, 129.4, 129.3, 128.3, 127.6, 127.3, 123.5, 38.2; 
MS (ESI) m/z calculated [M-H]-: 303.03; found [M-H]-: 303.98.
5-(4-chlorobenzyl)-1-cyclohexyl-1H-tetrazole (3g)
Colorless liquid, Yield: 132 mg (48%); 1H NMR (500 MHz, CDCl
3
) δ 7.30 (d, 
J = 8.3, 2H), 7.15 (d, J = 8.3, 2H), 4.26 (s, 2H), 4.11 – 3.99 (m, 1H), 1.99 – 1.83 (m, 
4H), 1.79 – 1.62 (m, 3H), 1.38 – 1.18 (m, 3H); 13C NMR (126 MHz, CDCl
3
) δ 152.3, 
133.6, 132.8, 129.8, 129.3, 129.2, 129.0, 128.8, 128.6, 57.9, 32.6, 28.9, 25.2, 25.1, 
24.7; MS (ESI) m/z calculated [M+H]+: 277.11; found [M+H]+: 277.24.
1-allyl-5-ethyl-1H-tetrazole (3h) 
Colourless liquid, Yield: 96 mg (70%); 1H NMR (500 MHz, CDCl
3
) δ 6.01 – 5.94 (m, 1H), 5.36 
(d, J = 10 Hz, 1H), 5.16 (d, J = 15 Hz, 1H), 4.97 (d, J = 5 Hz, 2H), 2.89 – 2.84 (q, J = 15 Hz, 
2H), 1.42 (t, J = 10 Hz, 3H); 13C NMR (126 MHz, CDCl
3
) δ 156.0, 130.1, 119.7, 49.2, 16.8, 11.3 
ppm; MS (ESI) m/z calculated [M+H]+: 139.09; found [M+H]+: 139.11.
5-ethyl-1-phenethyl-1H-tetrazole (3i) 
Brown liquid, Yield: 147 mg (73 %); 1H NMR (500 MHz, CDCl
3
) δ 7.39 – 7.18 (m, 3H), 6.98 
(d, J = 7.7, 2H), 4.46 (t, J = 6.8, 2H), 3.21 (t, J = 6.8, 2H), 2.35 (q, J = 7.6, 2H), 1.17 (t, J = 7.6, 
3H); 13C NMR (126 MHz, CDCl
3
) δ 156.2, 136.4, 129.0, 128.8, 128.7, 127.4, 48.5, 36.3, 16.4, 
11.2; MS (ESI) m/z calculated [M+H]+: 203.12; found [M+H]+: 203.19.
5-ethyl-1-phenyl-1H-tetrazole (3j)
Colorless liquid, Yield: 149 mg (86%); 1H NMR (500 MHz, CDCl
3
) δ 7.68 – 7.56 (m, 3H), 
7.52 – 7.41 (m, 2H), 2.93 (q, J = 7.6, 2H), 1.38 (t, J = 7.6, 3H); 13C NMR (126 MHz, CDCl
3
) 
δ 156.1, 133.8, 130.4, 129.9, 124.8, 17.5, 11.6; MS (ESI) m/z calculated [M+H]+: 175.09; 
found [M+H]+: 175.10.
3-(5-propyl-1H-tetrazol-1-yl)propanenitrile (3k) 
Colorless liquid, Yield: 99 mg (60%); 1H NMR (500 MHz, CDCl
3
) δ 4.61 (t, J = 6.6, 2H), 3.13 
(t, J = 6.6, 2H), 2.90 (t, J = 7.6, 2H), 1.97 – 1.81 (m, 2H), 1.06 (t, J = 7.4, 3H); 13C NMR (126 
MHz, CDCl
3
) δ 155.5, 116.1, 42.4, 24.8, 20.6, 18.7, 13.6; MS (ESI) m/z calculated [M+H]+: 
166.10; found [M+H]+: 166.13.
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Brown liquid, Yield: 167 mg (71%); 1H NMR (500 MHz, CDCl
3
) δ 7.37 – 7.18 (m, J = 5.1, 
1.6, 3H), 7.01 – 6.93 (m, 2H), 4.54 (t, J = 6.7, 2H), 3.66 (t, J = 6.9, 2H), 3.22 (t, J = 6.7, 2H), 
2.71 (t, J = 6.9, 2H); 13C NMR (126 MHz, CDCl
3
) δ 152.5, 136.3, 129.1, 129.0, 128.7, 128.7, 
127.5, 48.9, 40.6, 36.3, 26.3; MS (ESI) m/z calculated [M+H]+: 236.08; found [M+H]+: 
237.29.
5-(3-methoxyphenyl)-1-phenyl-1H-tetrazole (3m) 
Brown liquid, Yield: 182 mg (72%); 1H NMR (500 MHz, CDCl
3
) δ 7.57 – 7.51 (m, J = 7.8, 
3H), 7.41 (d, J = 7.2, 2H), 7.14 (s, 1H), 7.11 – 6.95 (m, 4H), 3.74 (s, 3H); 13C NMR (126 MHz, 
CDCl
3
) δ 159.8, 153.5, 134.6, 130.5, 130.1, 129.9, 128.9, 125.4, 121.1, 117.6, 113.9, 55.4; 
MS (ESI) m/z calculated [M+H]+: 253.10; found [M+H]+: 253.18.
1-(3,4-dimethoxyphenyl)-5-(4-nitrophenyl)-1H-tetrazole (3n) 
Yellow solid, Yield: 290 mg (87%); 1H NMR (500 MHz, CDCl
3
) δ 8.28 (d, J = 8.6, 
2H), 7.83 (d, J = 8.6, 2H), 6.98 – 6.92 (m, 2H), 6.87 (dd, J = 8.5, 2.2, 1H), 3.98 
(s, 3H), 3.88 (s, 3H); 13C NMR (126 MHz, CDCl
3
) δ 151.9, 151.1, 150.1, 149.3, 
129.9, 129.7, 128.9, 126.6, 124.1, 123.7, 118.0, 111.3, 108.7, 56.4, 56.3; MS (ESI) 
m/z calculated [M+H]+: 328.10; found [M+H]+: 328.18.
1-(2-benzylphenyl)-5-(4-chlorobenzyl)-1H-tetrazole (3o) 
Yellow liquid, Yield: 318 mg (88%); 1H NMR (500 MHz, CDCl
3
) δ 7.54 (td, J = 7.6, 
1.1, 1H), 7.41 (d, J = 7.6, 1H), 7.34 (td, J = 7.7, 1.2, 1H), 7.24 – 7.11 (m, 5H), 6.90 
(dd, J = 7.8, 0.8, 1H), 6.86 (d, J = 8.4, 2H), 6.79 (d, J = 6.6, 2H), 3.62 (s, 2H); 13C 
NMR (126 MHz, CDCl
3
) δ 154.5, 139.1, 138.1, 133.5, 132.4, 132.3, 131.6, 131.4, 
130.1, 128.9, 128.7, 128.7, 127.6, 127.4, 126.8, 37.4, 28.3; MS (ESI) m/z calculated [M+H]+: 361.11; found 
[M+H]+: 361.20.
5-(chloromethyl)-1-phenyl-1H-tetrazole (3p)
White solid, Yield: 141 mg (73%); 1H NMR (500 MHz, CDCl
3
) δ 7.68 – 7.47 (m, 5H), 4.83 (s, 2H); 
13C NMR (126 MHz, CDCl
3
) δ 151.6, 133.1, 131.0, 130.1, 124.7, 31.2; MS (ESI) m/z calculated 
[M+H]+: 195.04; found [M+H]+: 195.26.
5-(chloromethyl)-1-(o-tolyl)-1H-tetrazole (3q)
White solid, Yield: 150 mg (72%); 1H NMR (500 MHz, CDCl
3
) δ 7.51 (t, J = 7.6, 1H), 7.42 (d, 
J = 7.4, 1H), 7.38 (t, J = 8.0, 1H), 7.28 (d, J = 7.8, 1H), 4.66 (s, 2H), 2.04 (s, 3H); 13C NMR (126 
MHz, CDCl
3
) δ 152.4, 135.5, 131.9, 131.6, 127.3, 126.6, 30.9, 17.3; MS (ESI) m/z calculated 
[M+H]+: 209.05; found [M+H]+: 209.26.
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Yellow liquid, Yield: 199 mg (92%); 1H NMR (500 MHz, CDCl
3
) δ 7.28 (dd, J = 12.9, 5.2, 
2H), 7.23 (t, J = 7.2, 1H), 7.13 (d, J = 7.2, 2H), 3.93 (t, J = 7.3, 2H), 3.21 – 3.06 (m, 4H), 
1.81 – 1.67 (m, 2H), 0.86 (t, J = 7.4, 3H); 13C NMR (126 MHz, CDCl
3
) δ 154.1, 139.5, 128.8, 
128.4, 126.9, 48.3, 33.7, 25.6, 22.9, 10.9; MS (ESI) m/z calculated [M+H]+: 217.14; found 
[M+H]+: 217.20.
1-benzyl-5-phenethyl-1H-tetrazole (3s)
Brown solid, Yield: 190 mg (72%); 1H NMR (500 MHz, CDCl
3
) δ 7.42 – 7.34 (m, 3H), 7.33 
– 7.23 (m, 3H), 7.15 – 7.05 (m, 4H), 5.22 (s, 2H), 3.04 (s, 4H); 13C NMR (126 MHz, CDCl
3
) 
δ 154.4, 139.4, 133.3, 129.2, 128.9, 128.8, 128.4, 127.4, 126.9, 50.5, 33.5, 25.6; MS (ESI) 
m/z calculated [M+H]+: 265.14; found [M+H]+: 265.21.
5-(3,4-dimethoxybenzyl)-1-isopropyl-1H-tetrazole (3t)
Brown solid, Yield: 148 mg (56%);1H NMR (500 MHz, CDCl
3
) δ 6.81 (d, J = 8.2, 
1H), 6.71 (d, J = 8.3, 1H), 6.68 (d, J = 1.7, 1H), 4.48 (hept, J = 6.7, 1H), 4.24 (s, 2H), 
3.86 (s, 3H), 3.82 (s, 3H), 1.43 (d, J = 6.7, 6H); 13C NMR (126 MHz, CDCl
3
) δ 152.6, 
149.5, 148.5, 126.5, 120.4, 119.4, 111.4, 111.3, 111.1, 110.5, 55.9, 55.9, 50.7, 29.2, 
22.4; MS (ESI) m/z calculated [M+H]+: 263.14; found [M+H]+: 263.20.
5-(4-chlorobenzyl)-1-phenethyl-1H-tetrazole (3u)
Yellow liquid, Yield: 189 mg (63%); 1H NMR (500 MHz, CDCl
3
) δ 7.30 – 7.26 (m, 5H), 
6.98 – 6.88 (m, 4H), 4.32 (t, J = 6.9, 2H), 3.68 (s, 2H), 3.08 (t, J = 6.9, 2H); 13C NMR (126 
MHz, CDCl
3
) δ 153.5, 136.4, 132.2, 129.8, 129.3, 129.1, 128.7, 127.5, 48.9, 36.1, 28.2; MS 
(ESI) m/z calculated [M+H]+: 299.77; found [M+H]+: 299.11.
5-(naphthalen-2-ylmethyl)-1-propyl-1H-tetrazole (3v) 
Colorless solid, Yield: 184 mg (73%); 1H NMR (500 MHz, CDCl
3
) δ 7.82 – 7.78 
(m, 2H), 7.77 – 7.74 (m, 1H), 7.60 (s, 1H), 7.50 – 7.46 (m, 2H), 7.29 (dd, J = 8.4, 1.7, 
1H), 4.43 (s, 2H), 4.07 (t, J = 7.4, 7.2, 2H), 1.78 – 1.67 (m, 2H), 0.79 (t, J = 7.4, 3H); 
13C NMR (126 MHz, CDCl
3
) δ 153.4, 133.4, 132.6, 131.3, 129.1, 127.8, 127.6, 127.1, 
126.7, 126.4, 126.1, 48.9, 29.7, 22.8, 10.9; MS (ESI) m/z calculated [M+H]+: 253.14; 
found [M+H]+: 253.22.
1,5-diphenyl-1H-tetrazole (3w)
White solid, Yield: 124 mg (58%); 1H NMR (500 MHz, CDCl
3
) δ 7.62 – 7.44 (m, 2H), 7.41 
– 7.12 (m, 6H), 7.03 – 6.85 (m, 2H); 13C NMR (126 MHz, CDCl
3
) δ 154.5, 131.3, 130.5, 
129.9, 129.0, 129.0, 128.9, 128.4, 125.3; MS (ESI) m/z calculated [M+H]+: 223.09; found 
[M+H]+: 223.18.
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Yellow viscous liquid, Yield: 120 mg (48%); 1H NMR (500 MHz, CDCl
3
) δ 7.58 – 7.52 
(m, 1H), 7.47 (t, J = 7.6, 2H), 7.32 – 7.28 (m, 3H), 7.26 – 7.20 (m, 2H), 7.01 – 6.92 (m, 2H), 
4.63 (t, J = 7.1, 2H), 3.27 (t, J = 7.1, 2H); 13C NMR (126 MHz, CDCl
3
) δ 154.8, 136.1, 131.1, 
129.1, 128.9, 128.9, 128.7, 128.7, 127.3, 49.2, 36.1; MS (ESI) m/z calculated [M+H]+: 
251.12; found [M+H]+: 251.23.
1-(4-chlorophenyl)-5-(4-methoxyphenyl)-1H-tetrazole (3y)
Brown soild, Yield: 180 mg (63 %); 1H NMR (500 MHz, CDCl
3
) δ 7.54 – 7.46 (m, 
1H), 7.22 (d, J = 8.6, 2H), 7.09 (dd, J = 19.3, 8.6, 2H), 6.93 (d, J = 8.9, 1H), 6.87 – 6.76 
(m, 2H), 3.78 (s, 3H); 13C NMR (126 MHz, CDCl
3
) δ 162.0, 146.4, 130.5, 130.2, 129.3, 
126.6, 122.8, 114.9, 114.6, 114.4, 55.5; MS (ESI) m/z calculated [M+H]+: 287.06; 
found [M+H]+: 287.19.
3-(5-propyl-1H-tetrazol-1-yl)propanenitrile (3z)
Colorless liquid, Yield: 103 mg (62%); 1H NMR (500 MHz, CDCl
3
) δ 4.58 (t, J = 6.6, 2H), 
3.12 (t, J = 6.6, 2H), 2.90 (t, J = 7.6, 2H), 1.97 – 1.83 (m, 2H), 1.07 (t, J = 7.4, 3H); 13C NMR 
(126 MHz, CDCl
3
) δ 155.4, 115.9, 42.4, 24.9, 20.7, 18.8, 13.7; MS (ESI) m/z calculated 
[M+H]+: 166.10; found [M+H]+: 166.26.
1-phenethyl-5-propyl-1H-tetrazole (3aa)
Colorless liquid, Yield: 153 mg (71%); 1H NMR (500 MHz, CDCl
3
) δ 7.29 – 7.23 
(m, 3H), 7.02 – 6.96 (m, 2H), 4.46 (t, J = 6.9, 2H), 3.21 (t, J = 6.8, 2H), 2.31 (t, J = 7.6, 
2H), 1.63 – 1.54 (m, 2H), 0.86 (t, J = 7.4, 3H); 13C NMR (126 MHz, CDCl
3
) δ 155.1, 136.5, 
128.9, 128.7, 127.4, 48.5, 36.2, 24.5, 20.3, 13.6; MS (ESI) m/z calculated [M+H]+: 217.14; 
found [M+H]+: 217.23.
1-allyl-5-propyl-1H-tetrazole (3ab)
Yellow liquid, Yield: 79 mg (52%); 1H NMR (500 MHz, CDCl
3
) δ 6.04 – 5.89 (m, 1H), 5.36 (d, 
J = 10.3, 1H), 5.15 (d, J = 17.1, 1H), 4.96 (d, J = 5.6, 2H), 2.81 (t, J = 7.6, 2H), 1.99 – 1.76 (m, 
2H), 1.03 (t, J = 7.4, 3H); 13C NMR (126 MHz, CDCl
3
) δ 154.9, 130.2, 119.6, 49.2, 24.9, 20.4, 
13.6; MS (ESI) m/z calculated [M+H]+: 153.11; found [M+H]+: 153.16.
2-(1-phenethyl-1H-tetrazol-5-yl)acetonitrile (3ac) 
Colorless solid, Yield: 142 mg (67%); 1H NMR (500 MHz, CDCl
3
) δ 7.37 – 7.28 (m, 3H), 
6.96 (dd, J = 6.4, 2.8, 2H), 4.68 (t, J = 6.3, 2H), 3.24 (t, J = 6.4, 2H), 3.14 (s, 2H); 13C NMR 
(126 MHz, CDCl
3
) δ 146.3, 136.2, 129.5, 128.9, 128.0, 112.4, 49.9, 36.4, 12.9; MS (ESI) m/z 
calculated [M-H]-: 212.24; found [M-H]-: 212.16.
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Yellow solid, Yield: 130 mg (57%); 1H NMR (500 MHz, CDCl
3
) δ 7.68 (dd, J = 8.0, 1.1, 1H), 
7.66 – 7.61 (m, 1H), 7.59 – 7.48 (m, 2H), 4.75 (s, 2H); 13C NMR (126 MHz, CDCl
3
) δ 152.7, 
132.9, 131.2, 130.9, 130.8, 129.1, 128.3, 31.1; MS (ESI) m/z calculated [M+H]+: 229.00; 
found [M+H]+: 229.01.
1-benzyl-5-(chloromethyl)-1H-tetrazole (3ae) 
Colorless liquid, Yield: 130 mg (63%); 1H NMR (500 MHz, CDCl
3
) δ 7.45 – 7.36 (m, 3H), 
7.33 – 7.25 (m, 2H), 5.68 (s, 2H), 4.62 (s, 2H); 13C NMR (126 MHz, CDCl
3
) δ 151.1, 132.4, 
129.4, 129.4, 127.9, 51.7, 31.4; MS (ESI) m/z calculated [M+H]+: 209.05; found [M+H]+: 
209.05.
1-(2-chlorophenyl)-5-ethyl-1H-tetrazole (3af)
White solid, Yield: 125 mg (60%); 1H NMR (500 MHz, CDCl
3
) δ 7.65 (dd, J = 8.1, 1.4, 
1H), 7.60 (td, J = 7.8, 1.6, 1H), 7.52 (td, J = 7.7, 1.4, 1H), 7.43 (dd, J = 7.8, 1.6, 1H), 2.78 (q, 
J = 7.6, 2H), 1.35 (t, J = 7.6, 3H); 13C NMR (126 MHz, CDCl
3
) δ 157.3, 132.4, 131.6, 131.5, 
130.9, 128.9, 128.2, 17.0, 11.3; MS (ESI) m/z calculated [M+H]+: 209.05; found [M+H]+: 209.11.
1-benzyl-5-phenethyl-1H-tetrazole (3ag)
Colorless liquid, Yield: 182 mg (69%); 1H NMR (500 MHz, CDCl
3
) δ 7.37 – 7.31 (m, 3H), 
7.31 – 7.20 (m, 3H), 7.12 – 7.07 (m, 2H), 7.05 (d, J = 7.3, 2H), 5.20 (s, 2H), 3.01 (s, 4H); 13C 
NMR (126 MHz, CDCl
3
) δ 154.5, 139.5, 133.4, 129.2, 128.9, 128.8, 128.4, 127.4, 126.9, 
50.5, 33.4, 25.6; MS (ESI) m/z calculated [M+H]+: 265.14; found [M+H]+: 265.21.
5-phenethyl-1-propyl-1H-tetrazole (3ah) 
Colorless solid, Yield: 129 mg (60%); 1H NMR (500 MHz, CDCl
3
) δ 7.32 – 7.27 (m, 2H), 
7.25 – 7.20 (m, 1H), 7.13 (d, J = 7.1, 2H), 3.93 (t, J = 7.2, 2H), 3.22 – 3.14 (m, 2H), 3.14 – 
3.07 (m, 2H), 1.82 – 1.69 (m, 2H), 0.86 (t, J = 7.4, 3H); 13C NMR (126 MHz, CDCl
3
) δ 154.1, 
128.82, 128.4, 126.9, 48.3, 33.7, 25.6, 22.9, 10.9; MS (ESI) m/z calculated [M+H]+: 217.14; 
found [M+H]+: 217.16.
1,5-bis(4-chlorobenzyl)-1H-tetrazole (3ai) 
Colorless solid, Yield: 222 mg (70%); 1H NMR (500 MHz, CDCl
3
) δ 7.32 – 7.21 
(m, 4H), 6.98 (d, J = 8.3, 2H), 6.94 (d, J = 8.4, 2H), 5.31 (s, 2H), 4.13 (s, 2H); 13C NMR 
(126 MHz, CDCl
3
) δ 153.2, 135.1, 133.9, 131.8, 131.3, 129.7, 129.4, 129.3, 128.7, 
50.3, 28.9; MS (ESI) m/z calculated [M+H]+: 319.19; found [M+H]+: 319.14.
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Colorless solid, Yield: 150 mg (63%); 1H NMR (500 MHz, CDCl
3
) δ 7.62 – 7.54 (m, 3H), 
7.54 – 7.47 (m, 2H), 7.38 – 7.32 (m, 3H), 7.16 (dd, J = 7.1, 2.2, 2H), 5.62 (s, 2H); 13C NMR 
(126 MHz, CDCl
3
) δ 154.7, 133.9, 131.4, 129.2, 129.2, 129.1, 128.9, 128.8, 127.2, 123.8, 
123.5, 120.4, 51.4; MS (ESI) m/z calculated [M+H]+: 237.11; found [M+H]+: 237.12.
1,3-bis(5-benzyl-1H-tetrazol-1-yl)benzene (3ak) 
Yellow solid, Yield: 236 mg (60%); 1H NMR (500 MHz, CDCl
3
) δ 7.65 (t, J = 8.1, 1H), 
7.49 (dd, J = 8.1, 2.0, 2H), 7.26 – 7.17 (m, 7H), 7.04 (dd, J = 7.4, 1.4, 4H), 4.27 (s, 4H); 
13C NMR (126 MHz, CDCl
3
) δ 153.9, 134.7, 133.6, 131.2, 129.1, 128.5, 127.8, 126.7, 
121.9, 29.7; MS (ESI) m/z calculated [M+Na]+: 417.17; found [M+Na]+: 417.34.
1,3-bis(5-phenethyl-1H-tetrazol-1-yl)propane (3al) 
Yellow solid, Yield: 221 mg (57%); 1H NMR (500 MHz, CDCl
3
) δ 7.27 – 7.19 (m, 4H), 
7.19 – 7.13 (m, 2H), 7.06 (d, J = 7.2, 4H), 3.80 (t, J = 6.6, 4H), 3.20 – 3.04 (m, 8H), 2.00 
(p, J = 6.5, 2H); 13C NMR (126 MHz, CDCl
3
) δ 154.6, 139.2, 128.8, 128.6, 128.5, 126.9, 
43.2, 33.7, 28.0, 25.3; MS (ESI) m/z calculated [M+H]+: 389.21; found [M+H]+: 389.35.
1,3-bis(5-ethyl-1H-tetrazol-1-yl)propane (3am) 
Colorless solid, Yield: 145 mg (61%); 1H NMR (500 MHz, CDCl
3
) δ 4.35 (t, J = 6.7, 4H), 2.82 
(q, J = 7.6, 4H), 2.57 (p, J = 6.6, 2H), 1.31 (t, J = 7.6, 6H); 13C NMR (126 MHz, CDCl
3
) δ 156.2, 
63.6, 43.5, 28.4, 16.7, 11.2; MS (ESI) m/z calculated [M+H]+: 237.15; found [M+H]+: 237.12.
1,3-bis(5-(4-chlorobenzyl)-1H-tetrazol-1-yl)propane (3an) 
Colorless solid, Yield: 283 mg (66%); 1H NMR (500 MHz, CDCl
3
) δ 7.28 (d, J = 8.4, 4H), 
7.09 (d, J = 8.4, 4H), 4.25 (s, 4H), 4.12 (t, J = 6.5, 4H), 2.19 (p, J = 6.5, 2H); 13C NMR 
(126 MHz, CDCl
3
) δ 153.6, 133.9, 131.9, 129.8, 129.5, 43.7, 28.7, 28.2; MS (ESI) m/z 
calculated [M+H]+: 429.10; found [M+H]+: 429.20.
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Experiments for Proving Stereochemical Retention 
Synthesis of racemic compound: benzyl (1-(1-benzyl-1H-tetrazol-5-yl)ethyl)carbamate
Synthesized according to the general procedure.
benzyl (1-(1-benzyl-1H-tetrazol-5-yl)ethyl)carbamate 
White solid, Yield: 225 mg (67%); 1H NMR (500 MHz, CDCl
3
) δ 7.46 – 7.12 (m, 10H), 
6.50 (s, 1H), 5.06 (s, 2H), 4.49 – 4.32 (m, 2H), 4.32 – 4.15 (m, 1H), 1.39 (d, J = 7.0, 3H); 13C 
NMR (126 MHz, CDCl
3
) δ 172.1, 156.0, 137.9, 136.1, 128.7, 128.6, 128.3, 128.1, 127.6, 
127.6, 67.1, 50.6, 43.5, 18.6; MS (ESI) m/z calculated [M-H]-: 336.15; found [M-H]-: 336.24. The racemate 
was separated on a Reprosil Chiral-OM column as described in the general methods. Enantiomer A, 
t
R
 =3.42 min (48%); Enantiomer B, t
R
 = 3.63 min (52%).
Synthesis of (S)-benzyl (1-(1-benzyl-1H-tetrazol-5-yl)ethyl)carbamate (6) 
Synthesized according to the general procedure.
(S)-benzyl (1-(1-benzyl-1H-tetrazol-5-yl)ethyl)carbamate (6)
White solid, Yield: 220 mg (65%); 1H NMR (500 MHz, CDCl
3
) δ 7.43 – 7.27 (m, 7H), 
7.27 – 7.14 (m, 3H), 6.59 (s, 1H), 5.15 – 4.94 (m, 2H), 4.50 – 4.34 (m, 2H), 4.33 – 4.15 (m, 
1H); 13C NMR (126 MHz, CDCl
3
) δ 172.2, 156.0, 137.9, 136.1, 128.7, 128.6, 128.3, 128.1, 
127.6, 127.6, 67.1, 50.6, 43.5, 18.7; MS (ESI) m/z calculated [M-H]-: 336.15; found [M-H]-: 336.16. The 
enantiomeric excess was determined on a Reprosil Chiral-OM column as described in the general 
methods. Enantiomer A, t
R
 =3.43 min (>99.9%); Enantiomer B, t
R
 = 3.63 min (0%).
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Synthesis of Fused Tetrazoles:
Synthesized according to the general procedure.
Tetrazolo[1,5-c]quinazoline (9a)
White solid, Yield: 86 mg (50%); 1H NMR (500 MHz, CDCl
3
) δ 8.32 (d, J = 8.0, 1H), 8.15 (s, 
1H), 7.87 – 7.76 (m, 2H), 7.56 (t, J = 7.4, 1H); 13C NMR (126 MHz, CDCl
3
) δ 163.1, 149.0, 
143.4, 135.0, 127.9, 127.4, 126.4, 122.5; MS (ESI) m/z calculated [M+H]+: 172.05; found 
[M+H]+: 172.08.
4-benzyltetrazolo[1,5-a]quinoxaline (9b)
White solid, Yield: 159 mg (61%); 1H NMR (500 MHz, CDCl
3
) δ 7.54 – 7.46 (m, 2H), 
7.31 – 7.24 (m, 5H), 7.22 – 7.17 (m, 2H), 4.24 (s, 2H); 13C NMR (126 MHz, CDCl
3
) 
δ 153.4, 136.3, 129.8, 129.6, 129.0, 129.0, 127.9, 127.3, 122.4, 35.9; MS (ESI) m/z 
calculated [M+H]+: 262.10; found [M+H]+: 262.32.
4-methyltetrazolo[1,5-a]quinoxaline (9c)
White solid, Yield: 109 mg (59%); 1H NMR (500 MHz, CDCl
3
) δ 8.58 (dd, J = 7.5, 1.7, 1H), 
8.21 (dd, J = 7.1, 2.1, 1H), 7.89 – 7.79 (m, 2H), 3.13 (s, 3H); 13C NMR (126 MHz, CDCl
3
) 
δ 151.0, 142.8, 136.8, 131.9, 130.3, 129.8, 129.7, 116.3, 21.7; MS (ESI) m/z calculated 
[M+H]+: 186.07; found [M+H]+: 186.32.
4-ethyltetrazolo[1,5-a]quinoxaline (9d)
Pale yellow solid, Yield: 121 mg (61%); 1H NMR (500 MHz, CDCl
3
) δ 8.59 – 8.52 (m, 1H), 
8.26 – 8.16 (m, 1H), 7.87 – 7.78 (m, 2H), 3.49 (q, J = 7.5, 2H), 1.58 (t, J = 7.5, 3H); 13C NMR 
(126 MHz, CDCl
3
) δ 155.3, 136.8, 131.7, 130.7, 130.2, 129.9, 129.6, 116.2, 28.6, 11.3. MS 
(ESI) m/z calculated [M+H]+: 200.09; found [M+H]+: 200.26.
4-methyl-4,5-dihydrotetrazolo[1,5-a]quinoxaline (9e)
Colorless liquid, Yield: 119 mg (63%); 1H NMR (500 MHz, CDCl
3
) δ 10.73 (s, 1H), 7.72 
– 7.57 (m, 2H), 7.36 – 7.23 (m, 2H), 5.06 (q, J = 6.9, 1H), 1.84 (d, J = 6.9, 3H); 13C NMR 
(126 MHz, CDCl
3
) δ 153.2, 138.3, 123.1, 115.3, 55.3, 19.2; MS (ESI) m/z calculated [M+H]+: 
188.09; found [M+H]+: 188.13.
Tetrazolo[5,1-a]phthalazine (9f)
White solid, Yield: 82 mg (48%); 1H NMR (500 MHz, CDCl
3
) δ 8.99 (s, 1H), 8.76 (d, J = 8.0, 
1H), 8.19 (d, J = 8.0, 1H), 8.14 (t, J = 7.6, 1H). 13C NMR (126 MHz, CDCl
3
) δ 149.23, 142.10, 
134.88, 132.76, 128.62, 124.83, 124.58, 122.24; MS (ESI) m/z calculated [M+H]+: 172.05; 
found [M+H]+: 172.10.
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Brown solid, Yield: 97 mg (56%); 1H NMR (500 MHz, CDCl
3
) δ 7.94 (dd, J = 8.0, 1.4, 1H), 
7.36 (td, J = 8.0, 1.5, 1H), 7.22 (t, J = 7.8, 1H), 7.18 (dd, J = 8.3, 0.7, 1H), 5.64 (s, 2H); 13C 
NMR (126 MHz, CDCl
3
) δ 145.9, 144.9, 130.0, 123.7, 121.9, 118.1, 117.2, 62.1; MS (ESI) m/z 
calculated [M+H]+: 175.05; found [M+H]+: 175.20.
Procedure for 9h and 9i: 
A 20 ml microwave vial equipped with a magnetic stirring bar was charged with 6-aminohexanoic 
acid or 5-aminopentanoic acid (1.0 mmol) in CH
3
CN (5 ml) and phosphoryl chloride (1.0 mmol) was 
added slowly followed by trimethylsilyl azide (1.5 equiv) at room temperature. The vial was sealed 
with a cap containing a septum and subjected to microwave heating at 180 °C till completion of 
reaction. [attention: during irradiation, pressure develops] Then the reaction mixture was poured into 
50 mL of saturated NaHCO
3




. The solvent was removed 
under reduced pressure and residue was puriﬁed by silica gel ﬂash chromatography using EtOAc–
hexane or DCM:MeOH as eluent t. [Caution: Addition of reagents and work-up must be done behind the 
glass-hood.]
6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine (9h)
Colorless solid, Yield: 105 mg (76%); 1H NMR (500 MHz, CDCl
3
) δ 4.58 – 4.44 (m, 2H), 3.18 
– 3.05 (m, 2H), 2.07 – 1.95 (m, 2H), 1.94 – 1.85 (m, 2H), 1.84 – 1.72 (m, 2H); 13C NMR (126 
MHz, CDCl
3
) δ 156.6, 49.3, 29.8, 27.1, 24.6, 24.2; MS (ESI) m/z calculated [M+H]+: 139.09; 
found [M+H]+: 139.11.
5,6,7,8-tetrahydrotetrazolo[1,5-a]pyridine (9i)
Colorless solid, Yield: 88 mg (71%); 1H NMR (500 MHz, CDCl
3
) δ 4.34 (t, J = 6.1, 2H), 3.00 (t, J 
= 6.4, 2H), 2.19 – 2.07 (m, 2H), 2.06 – 1.93 (m, 2H); 13C NMR (126 MHz, CDCl
3
) δ 151.9, 45.5, 
22.2, 20.7, 19.9; MS (ESI) m/z calculated [M+H]+: 125.07; found [M+H]+: 125.03.
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Synthesis of 5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole (12)
A 20 ml microwave vial equipped with a magnetic stirring bar was charged with 2-(4-chlorophenyl)
acetic acid chloride (1.0 mmol), 2-phenylethanamine (1.0 mmol), and CH
3
CN (5 ml) and stirred 
at room temperature for 30 min followed by the addition of phosphoryl chloride (1.0 mmol) at 
room temperature. Trimethylsilyl azide (1.5 equiv) was added in the reaction mixture and subjected 
to microwave heating at 120 oC for 10 minute. Then the reaction mixture was added to a 25 ml 
saturated NaHCO
3
 solution and extracted in DCM. The solvent was removed under reduced pressure 
and the mixture was puriﬁed by ﬂash chromatography on silica gel (eluent: hexane/AcOEt) to aﬀord 
the titled compound as a white solid. Yield: 157 mg (65%); 1H NMR (500 MHz, CDCl
3
) δ 4.23 – 4.05 (m, 
1H), 3.62 (t, J = 6.2, 2H), 2.89 (t, J = 7.5, 2H), 2.07 – 1.95 (m, 8H), 1.95 – 1.88 (m, 2H), 1.83 – 1.75 (m, 1H), 
1.52 – 1.30 (m, 3H); 13C NMR (126 MHz, CDCl
3
) δ 153.3, 57.6, 44.2, 32.9, 31.5, 25.3, 24.8, 24.4, 22.5; MS 
(ESI) m/z calculated [M+H]+: 243.13; found [M+H]+: 243.24.
Synthesis of Cilostazol (14): 
5-(4-chlorobutyl)-1-cyclohexyl-1H-tetrazole 13 (0.25 mmol) and 6-hydroxy-3,4-dihydroquinolin-
2(1H)-one (0.275 mmol) were added to DMF (3 ml) in a 20 ml microwave vial followed by KOH (0.75 
mmol) and subjected to microwave heating at 150 °C for 7 min. Then reaction mixture was poured 
into water and extracted in ethyl acetate. The solvent was removed under reduced pressure and 
the mixture was puriﬁed by ﬂash chromatography on silica gel (eluent: DCM/MeOH) to aﬀord a 
cilostazol 14 as a colorless solid. Yield: 89%; 1H NMR (500 MHz, CDCl3) δ = 7.85 (s, 1H), 7.26 (s, 2H), 
6.78 – 6.62 (m, 3H), 4.21 – 4.05 (m, 1H), 3.98 (t, J = 6.0, 2H), 3.49 (d, J = 5.1, 1H), 2.99 – 2.87 (m, 4H), 2.61 
(m, 2H), 2.13 – 1.94 (m, 8H), 1.94 – 1.84 (m, 2H), 1.78 (d, J = 12.0, 1H), 1.50 – 1.32 (m, 3H); 13C NMR (126 
MHz, CDCl
3
) δ 170.9, 154.8, 153.5, 130.8, 125.2, 116.0, 114.5, 113.1, 67.6, 57.6, 32.9, 30.6, 28.6, 25.8, 25.3, 
24.8, 24.0, 23.0; MS (ESI) m/z calculated [M+H]+: 370.42; found [M+H]+: 370.34.
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